A Case of Exacerbation of Haloperidol-Induced Rhabdomyolysis Following the Onset of COVID-19

Keisuke Takada; Yukiyoshi Sada; Masaru Samura; Masashi Matsuura; Naoki Hirose; Takenori Kurata; Fumio Nagumo; Junichi Ishii; Sakura Koshioka; Masaki Uchida; Junki Inoue; Koji Tanikawa; Hiroyuki Kunishima

doi:10.12659/AJCR.936589

20 June 2022: Articles

A Case of Exacerbation of Haloperidol-Induced Rhabdomyolysis Following the Onset of COVID-19

Unusual clinical course, Challenging differential diagnosis, Adverse events of drug therapy

Keisuke Takada ^A* , Yukiyoshi Sada ^A , Masaru Samura ^A , Masashi Matsuura ^B , Naoki Hirose ^D , Takenori Kurata ^D , Fumio Nagumo ^D , Junichi Ishii ^D , Sakura Koshioka ^D , Masaki Uchida ^D , Junki Inoue ^D , Koji Tanikawa ^D , Hiroyuki Kunishima ^A

DOI: 10.12659/AJCR.936589

Am J Case Rep 2022; 23:e936589

Authors information Article notes Copyright and License information

Background Case Report Discussion Conclusions References:

View HTML version

Figure 2. Clinical course of the patient. RDV – remdesivir; DEX – dexamethasone; mPSL – methylprednisolone; TCZ – tocilizumab; CI – continuous infusion; CK – creatine phosphokinase; SCr – serum creatinine.

Back to the Article

A Case of Exacerbation of Haloperidol-Induced Rhabdomyolysis Following the Onset of COVID-19

Your Privacy